Statins: Can we advocate them for primary prevention of heart disease?

Published on Jul 1, 2014in Medical journal, Armed Forces India
· DOI :10.1016/J.MJAFI.2013.05.008
Sougat Ray7
Estimated H-index: 7
(Armed Forces Medical College),
A.K. Jindal7
Estimated H-index: 7
(Armed Forces Medical College)
+ 1 AuthorsS. N. Sinha10
Estimated H-index: 10
(Armed Forces Medical College)
Sources
Abstract
The discovery of cholesterol-lowering agents, namely HMG-CoA reductase inhibitors or statins, ushered in a series of large cholesterol reduction trials. The first of these studies was the Scandinavian Simvastatin Survival Study (4S) in which hypercholesterolemic men with CHD who were treated with simvastatin had a reduction in major coronary events of 44% and a reduction in total mortality of 30%. Many more secondary prevention trials followed to establish unequivocally the benefit of cholesterol reduction. Strategies that aim to improve primary prevention are important for managing the overall burden of disease. Recently therefore, the role of statin in primary prevention is being debated. The JUPITER trial and more recently the Cholesterol Treatment Trialists collaborators, proved that incidences of first major cardiovascular events in apparently healthy individuals were reduced by statins. Statins have also been discussed to be having certain pleiotropic effects on other diseases like diabetes, cancer and osteoporosis. However, issues of cost effectiveness and adverse effects like myositis, and transaminitis still loom large. The medical community needs to debate and evolve a possible consensus on the path breaking subject.
📖 Papers frequently viewed together
13 Citations
References23
Newest
#1Milan S. Geybels (UM: Maastricht University)H-Index: 17
#2Jonathan L. Wright (UW: University of Washington)H-Index: 46
Last. Janet L. Stanford (UW: University of Washington)H-Index: 98
view all 6 authors...
Background—We investigated associations between statin use begun before PCa diagnosis and prostate cancer (PCa) recurrence/progression and PCa-specific mortality (PCSM) in a prospective, population-based cohort study. Methods—The analysis included 1,001 PCa patients diagnosed in 2002–2005 in King County, Washington. Statin use was assessed at baseline using a detailed in-person interview. Prostate cancer recurrence/progression events and cause-specific survival were ascertained from a followup s...
50 CitationsSource
#1Eliano Pio Navarese (UMK: Nicolaus Copernicus University in Toruń)H-Index: 34
#2Antonino Buffon (UCSC: Catholic University of the Sacred Heart)H-Index: 26
Last. Jacek Kubica (UMK: Nicolaus Copernicus University in Toruń)H-Index: 30
view all 14 authors...
Recent reports indicate that statins are associated with an increased risk for new-onset diabetes mellitus (DM) compared with placebo and that this relation is dose dependent. The aim of this study was to perform a comprehensive network meta-analysis of randomized controlled trials (RCTs) investigating the impact of different types and doses of statins on new-onset DM. RCTs comparing different types and doses of statins with placebo were searched for using the MEDLINE, Embase, and Cochrane datab...
190 CitationsSource
#2Kirsten J. Ward (Lond: University of London)H-Index: 21
#7Shah Ebrahim (UoB: University of Bristol)H-Index: 150
Cardiovascular disease (CVD), which comprises heart attacks (myocardial infarction), angina and strokes, is ranked as the number one cause of mortality and is a major cause of morbidity world wide. High blood cholesterol is linked to CVD events and is an important risk factor. Reducing high blood cholesterol, is thus an important way to reduce the chances of suffering a CVD event. Statins - cholesterol lowering drugs - (e.g. simvastatin, pravastatin, atorvastatin) are the first-choice treatments...
1,318 CitationsSource
#2Borislava MihaylovaH-Index: 22
#3Jonathan EmbersonH-Index: 69
Last. Rory Collins (USYD: University of Sydney)H-Index: 165
view all 10 authors...
BACKGROUND Statins reduce LDL cholesterol and prevent vascular events, but their net effects in people at low risk of vascular events remain uncertain. METHODS This meta-analysis included individual participant data from 22 trials of statin versus control (n=134,537; mean LDL cholesterol difference 1·08 mmol/L; median follow-up 4·8 years) and five trials of more versus less statin (n=39,612; difference 0·51 mmol/L; 5·1 years). Major vascular events were major coronary events (ie, non-fatal myoca...
1,812 CitationsSource
#1Jose Gutierrez (Columbia University)H-Index: 26
#2Gilbert Ramirez (FIU: Florida International University)H-Index: 40
Last. Ralph L. SaccoH-Index: 157
view all 4 authors...
Background The effect of statins on the prevention of cardiovascular events is well demonstrated. Whether this protective effect is equal for women and men remains less well established. Our objective was to evaluate if statin therapy is equally effective in decreasing recurrent cardiovascular events in women and men. Data Sources Randomized clinical trials were searched in PubMed using as indexing terms (statins OR cholesterol lowering medications) AND (cardiovascular events OR stroke OR myocar...
142 CitationsSource
#1Patrizia Gazzerro (UNISA: University of Salerno)H-Index: 29
#2Maria ProtoH-Index: 20
Last. Maurizio BifulcoH-Index: 56
view all 9 authors...
Statins, among the most commonly prescribed drugs worldwide, are cholesterol-lowering agents used to manage and prevent cardiovascular and coronary heart diseases. Recently, a multifaceted action in different physiological and pathological conditions has been also proposed for statins, beyond anti-inflammation and neuroprotection. Statins have been shown to act through cholesterol-dependent and -independent mechanisms and are able to affect several tissue functions and modulate specific signal t...
320 CitationsSource
#1Marcello Tonelli (U of A: University of Alberta)H-Index: 138
#2Anita LloydH-Index: 16
Last. Braden J. MannsH-Index: 93
view all 10 authors...
Background: Statins were initially used to improve cardiovascular outcomes in people with established coronary artery disease, but recently their use has become more common in people at low cardiovascular risk. We did a systematic review of randomized trials to assess the efficacy and harms of statins in these individuals. Methods: We searched MEDLINE and EMBASE (to Jan. 28, 2011), registries of health technology assessments and clinical trials, and reference lists of relevant reviews. We includ...
107 CitationsSource
#1Lawrence D. Lazar (Cleveland Clinic)H-Index: 4
#2Mark J. PletcherH-Index: 59
Last. Lee GoldmanH-Index: 94
view all 5 authors...
Background—With wide availability of low-cost generics, primary prevention with statins has become less expensive. We projected the cost-effectiveness of expanded statin prescribing strategies using low-cost generics and identified conditions under which aggressive prescribing ceases to be cost-effective. Methods and Results—We simulated expanded statin prescribing strategies with the coronary heart disease policy model, a Markov model of the US population a35 years of age. If statins cost $4/mo...
125 CitationsSource
#1John W. McEvoy (Johns Hopkins University)H-Index: 29
#2Michael J. Blaha (Johns Hopkins University)H-Index: 83
Last. Steven R. Jones (Johns Hopkins University)H-Index: 34
view all 7 authors...
Baseline coronary artery calcification (CAC) accurately identifies coronary atherosclerosis and might improve prediction of future cardiac events. Serial assessment of CAC scores has been proposed for monitoring atherosclerosis progression and for assessing the effectiveness of medical therapies aimed at reducing cardiac risk. However, whether knowledge of progression of CAC scores over time further improves risk prediction is unclear. Several trials relating medical therapies to CAC progression...
195 CitationsSource
#1Kausik K. Ray (University of Cambridge)H-Index: 80
#2Sreenivasa RaoH-Index: 1
Last. Naveed SattarH-Index: 172
view all 8 authors...
Background: Statins have been shown to reduce the risk of all-cause mortality among individuals with clinical history of coronary heart disease. However, it remains uncertain whether statins have similar mortality benefit in a high-risk primary prevention setting. Notably, all systematic reviews to date included trials that in part incorporated participants with prior cardiovascular disease (CVD) at baseline. Our objective was to reliably determine if statin therapy reduces all-cause mortality a...
372 CitationsSource
Cited By5
Newest
#1Xiaodong Huang (Guangzhou Medical University)
#2Wei He (Beijing Jishuitan Hospital)H-Index: 2
Last. Chia-Ying Lin (UC: University of Cincinnati)
view all 7 authors...
To test the pharmacokinetics and toxicology of whole organs and tissues after intradiscal injection of simvastatin in rabbits. To provide the information needed to support human clinical trials. Twelve male and twelve female rabbits were randomly divided into four groups: control group (0 mg/ml), low dose group (0.1 mg/ml), medium dose group (1 mg/ml) and high dose group (10 mg/ml). Simvastatin at different concentrations of 10 μl was injected into L3/4, L4/5 and L5/6 intervertebral discs in eac...
Source
#1Liping AnH-Index: 2
#2Shoukuan An (HMU: Harbin Medical University)H-Index: 1
Last. Sha WangH-Index: 2
view all 11 authors...
: The aim of the present study was to investigate the effects and possible mechanisms of atorvastatin (Ato) against chronic heart failure (CHF). A rat model of CHF was established and cardiac functions were assessed using Echocardiography. The expression of RhoA/Rho kinase and endothelial nitric oxide synthase (eNOS) was assessed using western blotting and reverse transcription polymerase chain reaction following 4 weeks of treatment. The three groups assessed in the present study were as follow...
5 CitationsSource
#1Ali Moshiri (IUMS: Iran University of Medical Sciences)H-Index: 26
#2Ali Sharifi (UM: University of Malaya)H-Index: 32
Last. Ahmad Oryan (Shiraz University)H-Index: 45
view all 3 authors...
Osteoporotic fractures are a worldwide problem that increase mortality of elderly patients leaving a high cost to the world economy. In addition to exercise and supplementary regimens, medications and pharmaceutical agents are used for osteoporosis management. Anti-resorptive drugs particularly bisphosphonates are the classic option. However, anti-resorptive therapy alone may not be a suitable option for all the patients. Osteoporosis may occur as a result of increase in bone resorption, decreas...
4 CitationsSource
#1Ahmad Oryan (Shiraz University)H-Index: 45
#2Amir Kamali (Shiraz University)H-Index: 10
Last. Ali Moshiri (IUMS: Iran University of Medical Sciences)H-Index: 26
view all 3 authors...
Abstract Statins are known for their beneficial effects on cardiovascular diseases. Besides the lipid-lowering properties, statins exert their anabolic effects on the bone by differentiating mesenchymal cells to osteoblasts via upregulating BMP-2 and protecting osteoblasts from apoptosis. In addition, statins have been suggested to be anti-osteoclastic by reducing the osteoclast differentiation and activity. Several in vivo and clinical studies have confirmed the beneficial effects of statins in...
59 CitationsSource
Last. Juan C. Díaz-ZagoyaH-Index: 17
view all 9 authors...
Hyperlipidemia plays an important role in the development of atherosclerosis, the main cause of death in the world. In this study, the lipid-lowering effect of Carica papaya leaf in rats fed with a high cholesterol diet was evaluated. Daily doses of C. papaya extract 0, 31, 62 or 125 mg/kg body weight were orally administered in 300 μl polyethylene glycol to hypercholesterolemic rats; it was also administered 62 mg/kg body weight of the extract to rats with normal diet. After a 20-day treatment,...
Source